The Hidden Toll Collectors of Your Prescription: How Pharmacy Benefit Managers Shape What You Pay at the Pharmacy Counter

Most Americans understand, at least in broad terms, how health insurance works. You pay a premium, you receive coverage, and when you need care, your insurer picks up a portion of the bill. What far fewer Americans understand is that a separate — and enormously powerful — industry operates in the space between your insurer and the pharmacy where you fill your prescriptions. That industry belongs to pharmacy benefit managers, or PBMs, and their influence over what drugs you can access, at what price, and from which pharmacy is far greater than most patients realize.

What a Pharmacy Benefit Manager Actually Does

A pharmacy benefit manager is a third-party company that administers the prescription drug benefit on behalf of health insurers, employers, and government programs including Medicare Part D. In practical terms, PBMs negotiate with drug manufacturers over the price of medications, contract with pharmacy networks, process prescription drug claims, and determine which drugs appear on your plan's formulary — the official list of covered medications.

On paper, this arrangement sounds efficient. Insurers, many of which lack the infrastructure or expertise to manage drug benefits in-house, outsource that function to specialists who theoretically leverage their purchasing scale to extract better prices. In practice, however, the economics of PBM operations are far more complicated — and the outcomes for patients far less favorable — than that simple description implies.

Three companies — CVS Caremark, Express Scripts (now part of Evernorth, a Cigna subsidiary), and OptumRx (owned by UnitedHealth Group) — collectively manage an estimated 80 percent of all prescription drug claims in the United States. This extraordinary concentration of market power shapes virtually every aspect of how Americans receive and pay for medications.

The Rebate System: Who Benefits and Who Doesn't

At the center of the PBM business model is the rebate — a payment that drug manufacturers make to PBMs in exchange for favorable formulary placement. When a manufacturer wants its drug to appear on a plan's preferred tier (meaning lower out-of-pocket costs for patients), it negotiates a rebate with the PBM that administers that plan.

The arrangement creates a significant structural problem. PBMs have a financial incentive to favor drugs that generate large rebates over drugs that are simply the most effective or least expensive option for patients. A less costly generic medication may produce little or no rebate, while a higher-priced brand-name drug might generate substantial payments back to the PBM. The result can be formularies that steer patients toward expensive medications while relegating cheaper alternatives to higher cost-sharing tiers — or excluding them altogether.

Equally important is what happens to those rebates after they are collected. PBMs are not required to pass rebate savings directly to patients at the point of sale. In many cases, a significant share of the rebate revenue is retained by the PBM itself or passed to the insurer, rather than applied as a discount on the patient's copay or coinsurance. A patient filling a prescription for a brand-name drug may pay a substantial amount out of pocket while the PBM and insurer share a rebate that could have meaningfully reduced that cost.

Formulary Control and the Limits It Places on Patient Choice

Beyond rebates, PBMs exercise influence through their management of formularies and pharmacy networks. When a PBM places a drug on a high cost-sharing tier, or excludes it from coverage entirely, patients face a difficult choice: pay the full retail price out of pocket, ask their physician to prescribe an alternative, or navigate an often burdensome prior authorization process to argue for an exception.

Formulary decisions are made with limited transparency. Patients and even prescribing physicians frequently do not understand why a particular medication is covered at one tier rather than another, or why a drug that was covered last year has been moved or removed entirely. The criteria PBMs use to make these decisions are proprietary, and the appeals process for formulary exceptions can be slow and discouraging.

Pharmacy network restrictions present a related challenge. Many PBMs operate or have preferential relationships with specific pharmacy chains — including, in the case of CVS Caremark, a direct corporate parent. Patients may find that their preferred independent pharmacy is not included in their plan's preferred network, meaning they pay more to fill prescriptions there or must switch to a pharmacy they did not choose.

Mail-Order Mandates and the Pressure to Comply

A growing number of PBM-administered plans require patients who take maintenance medications — drugs taken regularly for chronic conditions — to fill prescriptions through a PBM-affiliated mail-order pharmacy after a certain number of retail fills. Patients who continue filling at a local pharmacy may face higher cost-sharing as a penalty for non-compliance.

Proponents argue that mail-order pharmacies offer cost savings and convenience, particularly for patients in rural areas. Critics point out that mail-order mandates eliminate patient choice, create logistical difficulties for individuals who need to speak directly with a pharmacist, and direct revenue toward PBM-affiliated operations rather than independent community pharmacies. For patients managing complex medication regimens, the inability to build a relationship with a consistent, accessible pharmacist is not a minor inconvenience — it is a genuine care coordination concern.

What Reform Efforts Are Attempting to Address

The opacity and market concentration of the PBM industry have attracted increasing attention from federal and state legislators, as well as from the Federal Trade Commission. The FTC launched an investigation into PBM practices in 2022 and published an interim report in 2024 documenting how large PBMs use their market position to inflate drug costs and disadvantage independent pharmacies and patients.

At the legislative level, reform proposals have focused on several key areas. Transparency requirements would compel PBMs to disclose the rebates they collect and what portion, if any, is passed to patients or plan sponsors. Pass-through pricing models would require that all manufacturer rebates and discounts be applied directly to patient costs at the point of sale, rather than retained as PBM revenue. Spread pricing bans would prohibit PBMs from charging insurers more for a drug than they reimburse the dispensing pharmacy — a practice through which PBMs extract additional margin from the system. Some proposals would also require greater separation between PBM operations and affiliated pharmacy and insurance entities, addressing the inherent conflicts of interest created by vertical integration.

Several states have enacted PBM regulations in recent years, with varying scope and enforcement mechanisms. Federal action, however, remains the most significant lever available given the interstate nature of most employer-sponsored health plans.

What Patients Can Do Now

Until broader systemic reform is enacted, patients have limited but meaningful options. Requesting a formulary exception — formally asking your insurer or PBM to cover a non-preferred or excluded medication at a lower cost-sharing tier — is a right guaranteed under most plans, and physicians can support these requests with clinical documentation. Comparing your plan's formulary against alternatives during open enrollment each year may reveal a plan whose covered medications better align with your needs. Asking your pharmacist to check whether a generic or therapeutic alternative is available at a lower tier can also yield savings.

Advocacy organizations, including patient groups and consumer health advocates, have published resources to help individuals understand and challenge PBM-driven formulary decisions. Engaging with those resources, and contacting your elected representatives to express support for PBM transparency legislation, contributes to the broader effort to bring accountability to a system that currently operates largely out of public view.

Pharmacy benefit managers are not going away. But an informed public — one that understands what PBMs do, how they profit, and where the conflicts of interest lie — is far better positioned to demand the reforms that would make the prescription drug system work for patients rather than against them.